Skip to content
Biodatica
Start free

Bristol-Myers Squibb

Dublin, Ohio

OncologyFiled/ApprovedListed · BMY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

Phase I trial registered: A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants

1w agoTrial registeredJul 9, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE4 registered

    Feb 24, 2026

    Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

    ClinicalTrials.gov · NCT06875960 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Aug 21, 2025

    Cancer · COMPLETED · sponsor: Bristol-Myers Squibb · Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig

    ClinicalTrials.gov · NCT07636863 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Jun 27, 2025

    Healthy Volunteers · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants

    ClinicalTrials.gov · NCT07063342 (opens the source filing in a new tab)

  4. Trial

    Study registered

    May 11, 2025

    Melanoma · COMPLETED · sponsor: Bristol-Myers Squibb · Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

    ClinicalTrials.gov · NCT07091695 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Oct 5, 2023

    Myelodysplastic Syndromes · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

    ClinicalTrials.gov · NCT06045689 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Apr 11, 2023

    Non-Hodgkin Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Rollover Study of CC-122

    ClinicalTrials.gov · NCT05688475 (opens the source filing in a new tab)

  7. Trial

    Study registered

    Aug 16, 2022

    Obstructive Hypertrophic Cardiomyopathy · RECRUITING · sponsor: Bristol-Myers Squibb · A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

    ClinicalTrials.gov · NCT05489705 (opens the source filing in a new tab)

  8. Trial

    PHASE1/PHASE2 registered

    May 5, 2022

    Carcinoma, Hepatocellular · COMPLETED · sponsor: Bristol-Myers Squibb · A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

    ClinicalTrials.gov · NCT05337137 (opens the source filing in a new tab)

  9. Trial

    Study registered

    Feb 16, 2022

    Gastric Cancer · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer

    ClinicalTrials.gov · NCT05165264 (opens the source filing in a new tab)

  10. Trial

    PHASE1/PHASE2 registered

    May 27, 2021

    Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms · RECRUITING · sponsor: Bristol-Myers Squibb · A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

    ClinicalTrials.gov · NCT04895709 (opens the source filing in a new tab)

  11. Trial

    Study registered

    Jul 1, 2019

    Rheumatoid Arthritis, Psoriatic Arthritis · COMPLETED · sponsor: Bristol-Myers Squibb · A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

    ClinicalTrials.gov · NCT05413044 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources